CHA₂DS₂-VASc Score Calculator
The CHA₂DS₂-VASc score estimates annual stroke risk in non-valvular atrial fibrillation from seven weighted factors (CHF, hypertension, age, diabetes, prior stroke, vascular disease, sex). Anticoagulation is generally recommended at ≥2 in men and ≥3 in women.
Inputs
Note: For non-valvular atrial fibrillation only. Does not apply to valvular AF, prosthetic valves, or moderate-to-severe mitral stenosis. Always pair with a bleeding-risk assessment (HAS-BLED) and shared decision-making.
Formula
Score = CHF (1) + HTN (1) + Age ≥75 (2) or 65–74 (1) + Diabetes (1) + Stroke/TIA/TE (2) + Vascular disease (1) + Female sex (1). Annual stroke risk (%) follows the Lip 2010 validation cohort.
Worked example
A 72-year-old woman with hypertension, heart failure, and a prior TIA scores: Age 65–74 = 1, Sex F = 1, HTN = 1, CHF = 1, Stroke = 2 → CHA₂DS₂-VASc 6, corresponding to ~9.7%/yr adjusted stroke risk.
Benchmarks
| Score | Annual stroke risk | Recommendation |
|---|---|---|
| 0 (male) | 0.2% | No anticoagulation |
| 1 (female alone) | 0.6% | No anticoagulation |
| 1 (male) / 2 (female) | 0.6–2.2% | Shared decision — consider OAC |
| ≥2 (male) / ≥3 (female) | ≥2.2% | OAC recommended |
Adjusted annual stroke rates from Lip 2010. Interpretive thresholds per 2019 ACC/AHA/HRS focused update on AFib.
Frequently asked
When is anticoagulation recommended?
Per the 2019 ACC/AHA/HRS focused update: score ≥2 in men and ≥3 in women meets the threshold for guideline-directed oral anticoagulation in non-valvular AF, absent contraindications.
Is female sex always a risk factor?
Female sex is a risk-modifier — it does not by itself indicate anticoagulation. A woman with a score of 1 (from sex alone) is treated like a man with a score of 0.
How does CHA₂DS₂-VASc differ from CHADS₂?
CHA₂DS₂-VASc adds age 65–74 (1), vascular disease (1), and female sex (1), and it weights age ≥75 as 2 rather than 1. It reclassifies many CHADS₂-low patients as intermediate and is now the guideline-preferred score.
Does the calculator apply to atrial flutter?
Yes — current guidelines recommend using CHA₂DS₂-VASc for stroke-risk assessment in atrial flutter as well as atrial fibrillation.
Should I use CHA₂DS₂-VASc after ablation or cardioversion?
Yes, at least in the short term. Long-term post-ablation anticoagulation decisions should be individualized because rhythm status alone does not fully modify baseline stroke risk.
References
- 1.Lip GYH et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest 2010;137(2):263–72. https://doi.org/10.1378/chest.09-1584
- 2.January CT et al. 2019 AHA/ACC/HRS Focused Update on the Management of Patients With Atrial Fibrillation. Circulation 2019;140(2):e125–e151. https://doi.org/10.1161/CIR.0000000000000665
- 3.Friberg L et al. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33(12):1500–10.
This calculator is for general planning and educational purposes only and is not clinical, legal, billing, or financial advice. Confirm all reimbursement, regulatory, and financial figures with a qualified professional and your organization's current policies before acting on anything here.